This work was supported by the National Key Research and Development Program of China(grant No.2021YFC2100600);National Natural Science Foundation of China(grant No.31830104);Science and Technology Commission of Shanghai Municipality(grant Nos.19JC1413000 and 19430750600)to L.B.We thank the Core Facility and Technical Service Center for SLSB and the Instrumental Analysis Center in SJTU for data collection.
Acarbose is a potent glycosidase inhibitor widely used in the clinical treatment of type 2 diabetes mellitus(T2DM).Various acarbose analogs have been identified while exploring compounds with improved pharmacological ...
Acarbose is used to control postpran-dial blood glucose in patients with type 2 diabetes and impaired glucose tolerance,since it improves insulin resistance and reduces blood lipids and cardiovascular complications.Ho...
The Natural Science Foundation of China(32160109,31800294);the Natural Science Foundation of Guangxi Province of China(2018GXNSFBA138006,2019AC20231);Educational Department of Guangxi(2018KY0089);the State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources(CMEMR2017-A07,2020-A09);Joint cultivation base of biology and medicine graduate student between Guangxi Normal University and Guilin Pharma Company.
Five new polychlorinated bibenzyls(1-5)along with 3 known compounds(6-8)were isolated from the stems and leaves of Rhododendron minutiflorum.The chemical structures of all the isolates were determined by spectroscopic...
Acarbose is an agent that has been used to treat type 2 diabetes for about 30 years;it prevents postprandial hyperglycemia by inhibiting carbohydrate digestion in the small intestine.Since incretin-based treatments ha...
Supported by National Natural Science Foundation of China(General Program);No.81670815;Guangdong Basic and Applied Basic Research Foundation,No.2020A1515010124,No.2021A1515010695;Special Fund for Innovation Strategy of Science and Technology plan of Guangdong Province,No.2019A030317011。
BACKGROUND Previous studies have shown that diabetes mellitus is a common comorbidity of coronavirus disease 2019(COVID-19),but the effects of diabetes or anti-diabetic medication on the mortality of COVID-19 have not...
This study is registered at Chinese Clinical Trial Registry Center.The registration number is ChiCTRTRC-08000231.
BACKGROUND The waist-to-height ratio(WHtR)is a promising anthropometric measure used to evaluate cardiovascular risk in diabetes and metabolic syndrome patients.The metformin and acarbose in Chinese as the initial hyp...
the National Natural Science Foundation of China(No.31470157,21661140002,31830104,U1703236);the Shanghai Science and Technology Committee(No.17JC1403600)。
Theα-glucosidase inhibitor acarbose is produced in large-scale by strains derived from Actinoplanes sp.SE50 and used widely for the treatment of type-2 diabetes.Compared with the wild-type SE50,a high-yield derivativ...
Objective To evaluate efficacy and safety of acarbose compared with metformin as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled with insulin.Methods This was a randomized,open-labeled...
We are grateful to Prof.Yuhui Sun from Wuhan university,China,and the late Prof.Keqian Yang from Institute of Microbiology,Chinese Academy of Sciences,for providing plasmids pWHU2653 and pDR-4-K^*,respectively.This work was supported by grants from the National Natural Science Foundation of China(No.31470157,21661140002);the Ministry of Science and Technology of China(No.2012AA02A706).
Theα-glucosidase inhibitor acarbose is commercially produced by Actinoplanes sp.and used as a potent drug in the treatment of type-2 diabetes.In order to improve the yield of acarbose,an efficient genetic manipulatio...